Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Tolerability of OCS-05 in Patients with Acute Optic Neuritis

Next Previous
Trial Profile

A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Tolerability of OCS-05 in Patients with Acute Optic Neuritis

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 08 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Privosegtor (Primary) ; Corticosteroid
  • Indications Optic neuritis
  • Focus Adverse reactions; First in man; Proof of concept
  • Acronyms ACUITY
  • Sponsors Accure Therapeutics; Oculis Pharma

Most Recent Events

  • 01 Apr 2025 According to an Oculis Pharma media release, company announced that it will host an in-person and virtual R&D Day on Tuesday, April 15, 2025 from 10:00 AM to 12:00PM ET at the Intercontinental New York Barclay hotel. The event will provide an update on Oculis portfolio of innovative late-stage clinical candidates, highlight recent clinical data and next steps, as well as discuss future development programs and business strategy and an expanded data analysis from the ACUITY Phase 2 trial.
  • 11 Mar 2025 According to an Oculis Pharma media release, FDA interactions are planned for the second half of 2025 to discuss the ACUITY trial results and align on the next steps, including a registrational development program for acute optic neuritis.
  • 06 Jan 2025 The protocol has been amended.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top